We Compiled the Most Important Fundamentals of Agilon Health Inc.

By Scott Lee • Monday, November 21 11:10 • Permanent Link

We're taking a closer look at Agilon Health Inc. today, as its shares have moved -5.0% compared to -0.5% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

Agilon Health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States.
Agilon Health inc. has moved -25.9% over the last year compared to -15.3% for the S&P 500 -- a difference of -10.5%
AGL has an average analyst rating of buy and is -44.71% away from its mean target price of $29.5 per share
Its trailing 12 month earnings per share (Eps) is $-1.0
Agilon Health Inc. has a trailing 12 month Price to Earnings (P/E) ratio of -16.4 while the S&P 500 average is 15.97
Its forward earnings per share (Eps) is $0 and its forward P/E ratio is None
AGL has a Price to Earnings Growth (PEG) ratio of 0.12, which shows the company is very undervalued compared to its earnings growth estimates.
The company has a Price to Book (P/B) ratio of 6.2 in contrast to the S&P 500's average ratio of 2.95
Agilon Health inc. is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07
Agilon Health inc. has on average reported free cash flows of $-105,485,000.00 over the last four years, during which time they have grown by an an average of -66.5%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.